---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-059329"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:12:54.193470+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics reports Q1 net loss $26M; GSBR-1290 Phase 2a obesity data due June 2024

## Summary
- Net loss $26.0M in Q1 2024 vs $18.0M in Q1 2023; cash $436.4M funds projected operations through at least 2026.
- Topline GSBR-1290 Phase 2a obesity 12-week data for 40 participants expected June 2024; Phase 2b obesity study to start Q4 2024.
- R&D expenses $20.7M (+58% YoY) driven by GLP-1R franchise; G&A expenses $11.3M (+74% YoY) from public company infrastructure.
- Plan to initiate first-in-human Phase 1 trial of LTSE-2578 (oral LPA1R antagonist for IPF) in June 2024.
- Amylin candidate selection expected Q4 2024; GIPR candidate selection H1 2025; ANPA-0073 (APJR) Phase 1 completed.

## SEC filing metadata
- accession: 0001104659-24-059329
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465924059329/0001104659-24-059329-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465924059329/tm2413721d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-059329
- JSON: https://secwatch.observer/filing/0001104659-24-059329.json
- Plain text: https://secwatch.observer/filing/0001104659-24-059329.txt

## Key facts
- Earnings Releases
  Structure Therapeutics Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 totaled $26.0 million.
  - Period: first quarter ended March 31, 2024
  - Net income: Net loss for the first quarter of 2024 totaled $26.0 million
  - Result: reported results
  source text: Structure Therapeutics Inc. (the "Company") issued a press release providing a corporate update and announcing its financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1888886/000110465924059329/0001104659-24-059329-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.